TRACON Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TCON Nasdaq 8731 https://www.traconpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals to Present at the Jefferies Healthcare Conference - Jun 2nd, 2023 12:00 pm
TRACON Pharmaceuticals Announces Poster Presentations for Envafolimab and TRC102 at the 2023 ASCO Annual Meeting - May 30th, 2023 12:00 pm
Q1 2023 TRACON Pharmaceuticals Inc Earnings Call - May 11th, 2023 3:24 pm
TRACON Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update - May 10th, 2023 8:02 pm
TRACON to Report First Quarter 2023 Financial Results and Provide Corporate Update on May 10, 2023 - May 3rd, 2023 8:02 pm
TRACON Pharmaceuticals Announces Arbitration Award in Dispute with I-Mab - Apr 25th, 2023 11:41 am
Runway Growth Finance Corp. Provides First Quarter 2023 Portfolio Update - Apr 6th, 2023 12:30 pm
Tracon (TCON) Moves to Buy: Rationale Behind the Upgrade - Mar 14th, 2023 4:00 pm
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2022 Earnings Call Transcript - Mar 10th, 2023 7:26 am
Q4 2022 TRACON Pharmaceuticals Inc Earnings Call - Mar 9th, 2023 10:49 am
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update - Mar 8th, 2023 9:02 pm
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023 - Feb 28th, 2023 9:02 pm
Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update - Jan 10th, 2023 1:30 pm
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023 - Dec 27th, 2022 1:00 pm
TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study - Dec 14th, 2022 4:29 pm
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial - Dec 14th, 2022 1:00 pm
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma - Nov 21st, 2022 1:00 pm
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 9:02 pm
TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022 - Oct 31st, 2022 12:00 pm
Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update - Oct 6th, 2022 12:30 pm